Shares of Epizyme Inc. (NASDAQ:EPZM) hit a new 52-week low during trading on Thursday . The company traded as low as $8.05 and last traded at $8.19, with a volume of 549,814 shares trading hands. The stock had previously closed at $8.69.

A number of analysts have commented on EPZM shares. Leerink Swann restated a “buy” rating on shares of Epizyme in a research note on Tuesday, April 19th. Cowen and Company restated a “buy” rating on shares of Epizyme in a research note on Monday, June 20th. Mizuho restated a “buy” rating and set a $18.00 price target on shares of Epizyme in a research note on Monday, June 20th. Royal Bank Of Canada restated an “outperform” rating and set a $26.00 price target on shares of Epizyme in a research note on Monday, June 20th. Finally, JMP Securities restated a “buy” rating and set a $28.00 price target on shares of Epizyme in a research note on Thursday, June 23rd. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Epizyme has a consensus rating of “Buy” and an average price target of $23.11.

The firm’s 50-day moving average is $9.88 and its 200-day moving average is $10.44. The company’s market capitalization is $476.55 million.

Epizyme (NASDAQ:EPZM) last announced its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.49) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.03. Equities research analysts forecast that Epizyme Inc. will post ($2.19) EPS for the current year.

In other Epizyme news, insider Robert A. Copeland sold 4,000 shares of the firm’s stock in a transaction on Monday, August 1st. The stock was sold at an average price of $10.37, for a total transaction of $41,480.00. Following the completion of the transaction, the insider now owns 35,538 shares of the company’s stock, valued at $368,529.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

A hedge fund recently raised its stake in Epizyme stock. Jennison Associates LLC boosted its stake in shares of Epizyme Inc. (NASDAQ:EPZM) by 252.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 893,913 shares of the biopharmaceutical company’s stock after buying an additional 640,245 shares during the period. Jennison Associates LLC owned 2.14% of Epizyme worth $14,320,000 at the end of the most recent reporting period.

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.